Cipla Limited has appointed Dinesh Jain as its Global Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective July 24, 2026. The Board of Directors approved the appointment and associated changes in authorised officers under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, during a meeting held on July 23, 2026. This leadership transition aims to align the company’s financial strategy with its broader business objectives.

The Board meeting commenced at 9:15 a.m. IST and concluded at 1:00 p.m. IST on July 23, 2026. Consequently, Ashish Adukia ceased to be the Global CFO and KMP at the close of business hours on July 23, 2026, transitioning to an internal business leadership role within the company. The disclosure was made in compliance with SEBI Listing Regulations and published on the company’s website under the Investors Section.

Dinesh Jain brings over three decades of experience to the role, having previously served as Head – Corporate Finance at Cipla Limited. His expertise spans strategic planning, corporate finance, accounting, taxation, treasury, financial planning and analysis (FP&A), and corporate governance. He has also led significant initiatives in mergers, amalgamations, and corporate restructuring. As a qualified Chartered Accountant and member of the Institute of Chartered Accountants of India, Jain’s background in business valuation, fundraising, due diligence, regulatory matters, and stakeholder management is expected to support the company’s financial operations.

Updated Contact Details for KMPs and Authorised Officers

The following table lists the contact details for Cipla Limited’s Key Managerial Personnel and officers authorised under Regulation 30(5) of the SEBI Listing Regulations:

The appointment underscores Cipla’s focus on strengthening its financial leadership team to navigate complex regulatory environments and drive strategic growth.

Cipla Limited reported a 39.2% year-on-year decline in consolidated net profit to ₹785.55 crore for the quarter ended June 30, 2026, down from ₹1,291.61 crore in the corresponding period of the previous year. The decline was driven by margin contraction and exceptional costs related to new labour codes, even as revenue registered modest growth. The Board of Directors approved the unaudited financial results at its meeting held on July 23, 2026.

Q1 Financial Performance

Total revenue from operations for the quarter stood at ₹7,119.28 crore, a 2.3% increase compared to ₹6,957.47 crore in Q1FY26. However, total expenses rose to ₹6,248.25 crore from ₹5,446.10 crore year-on-year. The company reported an exceptional loss of ₹275.91 crore in the previous fiscal year ended March 31, 2026, primarily due to an incremental gratuity and leave liability arising from the implementation of the New Labour Codes effective November 21, 2025.

Operational and Regulatory Updates

The company noted that effective April 1, 2026, it changed its presentation policy for marketing and promotional expenditures, now recording them as a reduction from Revenue from Operations rather than under Other Expenses. This change impacts revenue comparability but does not affect Profit for the period or Earnings per Share. Additionally, the paid-up equity share capital increased to ₹161.57 crore during the quarter following the allotment of shares under employee stock option schemes.

Cipla continues to face demand notices from the National Pharmaceutical Pricing Authority (NPPA) regarding alleged overcharges. The aggregate amount under litigation stands at ₹2,011 crore, comprising a principal of ₹863 crore and interest of ₹1,148 crore. The company has stated it expects a favourable outcome and has not made any provisions for these demands.

Segment Performance

One India delivered its highest-ever quarterly revenue of ₹3,452 crore, growing 12% year-on-year. This performance was driven by double-digit growth in chronic therapies such as Respiratory, Urology, Anti-diabetes, and Cardiac. The company maintained its rank as the second-largest player in overall chronic therapies, with the chronic mix improving to 60.4%. Key brands like Foracort, Duolin Syncrobreathe, and Doloneuron contributed to the growth.

North America reported revenue of $162 million, highlighted by the launch of the first AB-rated gVentolin with Complex Generic Technology (CGT). One Africa revenue stood at $103 million, up 1% year-on-year, with South Africa's private business growing faster than the market. Emerging Markets and Europe recorded revenue of $106 million, a 5% increase, continuing their growth trajectory.